Skip to content

Don’t invest unless you’re prepared to lose all the money you invest. You are unlikely to be protected if something goes wrong. Take 2 mins to learn more

Calculus portfolio companies contributing to the fight against COVID-19

While the global pandemic continues to affect our everyday lives, it is important to adapt quickly to a fast changing environment. Several of our portfolio companies have rapidly pivoted to play their part in the fight against COVID-19, and we would like to highlight their efforts below.

Mologic

  • A medical diagnostics firm Omega Diagnostics has CE-Marked Mologic’s first generation ELISA antibody test for Covid-19 to be used on patient samples sent by hospitals or GPs.
  • The CE-Mark follows successful independent validation of the test by the Liverpool School of Tropical Medicine and St George’s, University of London. The clinical performance of the test showed a 99% sensitivity and 98% specificity result. The test has also been submitted to Public Health England for formal validation. Read more
Boris Johnson visits Mologic’s lab in March 2020

Genedrive

  • As the global spread of COVID-19 infection increases, it is likely that a variety of diagnostic tools will be needed for direct clinical care via specialist laboratories, central hospital labs and in the community.
  • Genedrive will deliver clinically verified, consistent and reproducible assays that are easy to use and can be manufactured and delivered globally in high volume.
  • Genedrive entered into an agreement with Cytiva (formerly GE Healthcare Life Sciences) for the development of its Genedrive® 96 SARS-CoV2 assay for use on lab-based PCR instruments. Read more

Scancell

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

I have read and understood this important information

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

I have read and understood this important information